Arsenic trioxide, a therapeutic agent for APL. (Q34435492)

2 August 2017

1 reference

title

Arsenic trioxide, a therapeutic agent for APL. (English)

1 reference

2 August 2017

1 reference

T D Zhang

1

1 reference

2 August 2017

G Q Chen

2

1 reference

2 August 2017

Z G Wang

3

1 reference

2 August 2017

Z Y Wang

4

1 reference

2 August 2017

S J Chen

5

1 reference

2 August 2017

Z Chen

6

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

2 August 2017

1 reference

2 August 2017

20

1 reference

2 August 2017

7146-7153

1 reference

2 August 2017

49

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1204762

2 August 2017

0 references

cites work

Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Treatment of acute promyelocytic leukemia with arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Mitochondrion as a novel target of anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Is the human carcinogen arsenic carcinogenic to laboratory animals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Ancient remedy performs new tricks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Current issues in the management of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

The thrombophilic state in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Differentiation and apoptosis induction therapy in acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Apoptosis. Mitochondria--the death signal integrators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Arsenic--new life for an old potion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Induction of mitosis-mediated apoptosis by sodium arsenite in HeLa S3 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Arsenic trioxide, a novel mitochondriotoxic anticancer agent?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Arsenic and apoptosis in the treatment of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1204762

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1204762

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference